title: Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs.
abstract: Liposomes and immunoliposomes containing cytotoxic agents may be highly efficacious in intracavity therapy of malignancies confined principally to the peritoneal cavity. To assess the feasibility of this locoregional treatment, we prepared two derivatives of 5-fluorouridine (5-FUR), a highly cytotoxic metabolite of 5-fluorouracile, and incorporated them into REV liposomes, prepared with the reverse phase evaporation method. Encapsulation efficiency, drug leakage, and stability were determined, and size analysis and differential scanning calorimetry were carried out to evaluate the drug delivery potential of liposomes containing 5'-palmitoyl-5-FUR, 5'-succinyl-5-FUR, or the parent drug 5-FUR. The most suitable drug for encapsulation, in terms of minimum leakage and encapsulation efficiency, was 5'-palmitoyl-5-FUR, which differential scanning calorimetry indicated as being firmly anchored to the lipid bilayer. Thus, 5'-palmitoyl-5-FUR was chosen to prepare a chemotherapeutic liposome-monoclonal antibody conjugate (immunoliposome). The covalent linkage between antibody and liposome was realized by coupling the thiolated monoclonal antibody AR-3 with REV liposomes, containing N-[4-(p-maleimidophenyl)butyryl]phosphatidylethanolamine. The cytotoxic activity of drug-bearing liposomes and immunoliposomes was evaluated on the HT-29 human colon adenocarcinoma cell line; the immunoliposomes had higher cytotoxicity than liposomes or 5-FUR. To explore the potential of these drug formulations in anticancer therapy, we ip injected liposomes or immunoliposomes into athymic mice ip grafted with human HT-29 cell line. In this mouse model, the immunoliposome containing 5'-palmitoyl-5-FUR displayed the best antitumoral activity, since on day 27 postgraft only 5% of residual tumor mass was present, compared to control mice; there was a close relationship between exposure time of tumor tissue to the drug and antitumor potency.
authors.affiliation: Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Crosasso
authors.forename: P
authors.initials: P
authors.lastname: Brusa
authors.forename: F
authors.initials: F
authors.lastname: Dosio
authors.forename: S
authors.initials: S
authors.lastname: Arpicco
authors.forename: D
authors.initials: D
authors.lastname: Pacchioni
authors.forename: F
authors.initials: F
authors.lastname: Schuber
authors.forename: L
authors.initials: L
authors.lastname: Cattel
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002152:Calorimetry, Differential Scanning; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D004337:Drug Carriers; D004354:Drug Screening Assays, Antitumor; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008081:Liposomes / Q000737:chemistry / Q000276:immunology; D051379:Mice; D009368:Neoplasm Transplantation; D011355:Prodrugs / Q000008:administration & dosage / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014529:Uridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C107460:5'-palmitoyl-5-fluorouridine; C107459:5'-succinyl-5-fluorouridine; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D011355:Prodrugs; C001943:5-fluorouridine; D014529:Uridine